U.S. Antiarthritis Markets

Frost & Sullivan, February 2001

Market Leaders Focus on Technology

Recent advances in drug discovery by biotechnology companies have jump-started
languishing antiarthritis markets. Biotechnology industry participants
long ago recognized the many untapped opportunities in the arthritis market.
Now, they are at the forefront with immune system discoveries works and

innovations for treatments and possibly prevention of rheumatoid arthritis
(RA).

This Frost & Sullivan research evaluates the current state of the U.S. prescription
arthritis market. It forecasts revenues, growth, and product pricing in
three major segments, and covers present and future therapies. Market drivers,
restraints, demand analysis and more empowers your success.

Marketing Innovations Key to Maximizing Return

Research shows that of an estimated 43 million people afflicted with arthritis
in the U.S., only about eight percent are receiving treatment. Successful manufacturers

of antiarthritic treatments must educate users and the healthcare

industry about new drug discoveries through aggressive marketing campaigns
to become market winners.

The growing percentage of the U.S. population suffering from arthritis can
make demand skyrocket for antiarthritic drugs, states the author of this
research.

New Opportunities with Accelerated Market Acceptance

Antiarthritic markets are expected to grow with the introduction of new
drugs and treatments. New disease-modifying anti-rheumatic drugs (DMARDs)
are the first of their kind in a generation.

Most of the DMARDs have been available in the market for decades, some
for 70 years, in the treatment of RA, states the author. This market got a
new life with the launch of products which gained immediate acceptance.
Arthritis is one of the most prevalent diseases in America. This Frost &
Sullivan research offers an in-depth analysis of the U.S. antiarthritis markets. It
highlights the treatments available for RA, the most debilitating form of arthritis,

and reports on new treatments and drug development which hold the key
to market's future.

This Frost & Sullivan report presents a clear look at the opportunities and
threats in individual market areas, by providing your company with tools necessary
to excel in the U.S. Antiarthritis Markets.

- Introducing the Market Engineering Consulting Report

- Overview

- Executive Summary

- Introduction to the U.S. Prescription Arthritis Market

- Objectives and Purpose

- Report Scope and Segmentation

- Report Structure

- Current Treatments

Customers who bought this item also bought

• U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
• Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
• Rheumatoid Arthritis Therapeutics - Global Strategic Business Report
• The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis
• The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage Analysis
• United States Market for Rheumatoid Arthritis Pharmacotherapeutics
• Rheumatoid Arthritis (Event Driven)
• Global Rheumatoid Arthritis Drug Pipeline Capsule - 2012 Update
• Chinese Markets for Arthritis Treatment Drugs
• Global Psoriatic Arthritis Epidemiology and Patient Flow Analysis - 2012